Disclosures: Yashbir Singh: Nothing to Disclose, John Eaton: Nothing to Disclose, Sudhakar Venkatesh: Nothing to Disclose, Shahriar Faghani: Nothing to Disclose, Mette vesterhus: Nothing to Disclose, Tom Karlsen: Nothing to Disclose, Kristin Jorgensen: Nothing to Disclose, Trine Folseraas: Nothing to Disclose, Kosta Petrovic: Nothing to Disclose, Anne Negrd: Nothing to Disclose, Aliya Gulamhusein: Advanz: Consultant, Cymabay: Consultant, Gregory Gores: Nothing to Disclose, Sumera Ilyas: Astrazeneca: Consultant, Timucin Taner: Nothing to Disclose, Julie Heimbach: Nothing to Disclose, Nicholas LaRusso: NIH: R01 DK 24031, NIH: R01 DK 57993, NIH: P30 DK 84567, NIH: P30 DK90728, NIH: R01 DK117133, NIH: T32 DK 07198, Konstantinos Lazaridis: Nothing to Disclose, Bradley Erickson: Nothing to Disclose 2341 THE PREVALENCE OF INTESTINAL FAILURE-ASSOCIATED LIVER DISEASE (IFALD) IN PATIENTS ON LONG-TERM HOME PARENTERAL NUTRITION Nicholas Wan 1 Sharifah Syed Mustaffah 2 Andrew Holt 2 Richard Woodman 3 Shailesh Bihari 2 Steven Galluccio 2 Sumudu Narayana 2 Qun Chen 2 Maria Kielpikowska 2 Kate Muller 2 Jeyamani Ramachandran 2 Rachel Wundke 2 Rosalie Altus 2 Alan Wigg 2 , 1 Lyell McEwin Hospital, 2 Flinders Medical Centre, 3 Flinders University Background: Intestinal failure-associated liver disease (IFALD) is a recognized complication of long-term parenteral nutrition (PN)
After your initial health assessment, you'll be contacted by an expert clinician
Her nurse practitioner told her to stop taking Ozempic in October 2023 because of severe side effects, including persistent vomiting
Mounjaro users achieve greater average weight loss (18.4%) than those using Wegovy (14.9%) and Ozempic (15%)
Experiment with different times and consult with your healthcare provider to find the best schedule for you
